Eli Lilly and Company
813.53-6.57 (-0.8%)
Oct 29, 4:00:02 PM EDT · NYSE · LLY · USD
Key Stats
Market Cap
729.29BP/E (TTM)
53.21Basic EPS (TTM)
15.29Dividend Yield
0.01%Recent Filings
8-K
Lilly seals $6B debt deal
Eli Lilly closed a $6 billion debt offering on August 20, 2025, issuing floating-rate notes due 2028 and fixed-rate notes maturing from 2028 to 2065 at rates from 4.000% to 5.650%. Net proceeds hit $6.71 billion after underwriting discounts, bolstering liquidity amid growth demands. The company can redeem most notes early, but floating ones lock in until maturity. Default risks could accelerate payments.
8-K
Lilly Q2 revenue soars 38%
Eli Lilly reported Q2 2025 revenue of $15.56 billion, up 38% year-over-year, fueled by 68% growth in Mounjaro to $5.20 billion and 172% surge in Zepbound to $3.38 billion, while gross margin hit 84.3%. The company raised full-year revenue guidance to $60-62 billion and non-GAAP EPS to $21.75-23.00, reflecting robust demand yet offset by pricing pressures. Acquisitions of SiteOne Therapeutics and Verve Therapeutics bolster the pain and cardiovascular pipelines. Pipeline advances shine.
10-Q
Q2 FY2025 results
Eli Lilly's Q2 revenue surged 38% year-over-year to $15.6B, propelled by Mounjaro and Zepbound in cardiometabolic health, which together drove 68% and 172% growth respectively, while U.S. sales climbed 38% on volume gains offset by softer pricing. Gross margins expanded to 84.3% from 80.8%, thanks to better production costs and product mix, fueling a 91% jump in net income to $5.7B and diluted EPS to $6.29 (up 92%). Operating cash flow hit $4.8B for the half-year, yielding free cash flow of $1.5B (derived) after $3.2B capex, with cash at $3.4B and total debt at $39.9B following $6.5B notes issuance. July deals for Verve ($1.0B cash plus CVR) and SiteOne (up to $1.0B) bolster the pipeline. Yet pricing pressures from the IRA loom large.
8-K
Lilly shareholders approve directors, reject reforms
Eli Lilly shareholders convened their 2025 annual meeting on May 5, electing directors Ralph Alvarez, Mary Lynne Hedley, Kimberly Johnson, and Juan Luciano to three-year terms amid strong support exceeding 90% for most nominees. They approved executive compensation on an advisory basis and ratified Ernst & Young as auditors, yet rejected proposals to declassify the board and eliminate supermajority voting, falling short of the 80% threshold. Shareholder turnout hit 89%. Governance changes stalled.
10-Q
Q1 FY2025 results
Eli Lilly's Q1 revenue surged 45% year-over-year to $12.7B, propelled by Mounjaro and Zepbound, which together drove over $6B in sales amid robust demand, though offset by lower realized prices. Gross margin expanded to 82.5% from 80.9%, thanks to better production costs and product mix, fueling a 23% rise in net income to $2.8B and diluted EPS to $3.06 on 900.6 million shares. Operating cash flow hit $1.7B, but free cash flow turned negative at -$844M after $1.5B in capex; cash stood at $3.1B while debt climbed to $38.5B following a $6.5B note issuance to fund the Scorpion Therapeutics IPR&D acquisition, expensed at $1.6B. The company repurchased $1.2B in shares. Yet pricing pressures from payers and the IRA loom large.
IPO
Website
Employees
Sector
Industry
ABBV
AbbVie Inc.
225.14-2.40
AMGN
Amgen Inc.
291.77-0.32
AZN
Astrazeneca PLC
82.23-0.38
BIIB
Biogen Inc.
147.86-1.27
BMY
Bristol-Myers Squibb Company
42.60-0.22
JNJ
Johnson & Johnson
186.60-0.33
MRK
Merck & Company, Inc.
86.58-0.45
PFE
Pfizer, Inc.
24.29-0.21
TAK
Takeda Pharmaceutical Company L
13.77-0.33
VTRS
Viatris Inc.
10.27-0.02